Subscribe for the newsletter
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Epidermolysis Bullosa
Sort By
Newest First
Sign in
1 / 1
1 / 1
Rare Diseases
Staying Agile to Bring Therapies to Patients with Rare Diseases
Sheila Frame
Amryt Pharma
PAO-06-022-CL-08
Jun 21, 2022
Treatment
Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Castle Creek Pharmaceuticals
PR-M08-18-NI-120
Aug 31, 2018
Joint Venture
RegeneRx Licensee GtreeBNT Enters into Joint Venture to Globally Develop RGN-137 for Treatment of Epidermolysis Bullosa
RegeneRx
PR-M08-18-NI-039
Aug 10, 2018
